Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 11/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516337 | 1.00 | MTNR1B (0.36) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL339504 | 1.00 | MTNR1B (0.36) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL14206606 | 0.91 | HTR2A (0.34) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL803827 | 0.80 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL1555293 | 0.78 | PARP1 (0.32) | — | |
| SCHEMBL12394472 | 0.77 | MTNR1A (0.40) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL4688545 | 0.76 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL338471 | 0.76 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL338470 | 0.76 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL805876 | 0.75 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116531-A | Preparation method of ramelteon intermediate | 山东省食品药品检验研究院 | 2020-05-08 | — | — | CN | claimed |
| EP-2406242-B1 | PROCESS FOR THE PREPARATION OF RAMELTEON | IND CHIMICA SRL (IT) | 2013-06-05 | — | — | EP | claimed |
| US-8242291-B2 | Process for the preparation of ramelteon | INDUSTRIALE CHIMICA S.R.L. (IT) | 2012-08-14 | — | — | US | claimed |
| EP-2406242-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Industriale Chimica S.R.L. (IT) | 2012-01-18 | — | — | EP | claimed |
| WO-2011027319-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | claimed |
| US-20100234622-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | INDUSTRIALE CHIMICA S.R.L (IT) | 2010-09-16 | — | — | US | claimed |
| WO-2010103553-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | INDUSTRIALE CHIMICA S.R.L. (IT) | 2010-09-16 | — | — | WO | claimed |
| WO-2010041271-A2 | PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF | USV LIMITED (IN) | 2010-04-15 | — | — | WO | claimed |
| CN-118546047-B | Preparation method of cyclic chiral nitrile compound and application of cyclic chiral nitrile compound in preparation of ramelteon | 北京师范大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-118546047-A | Preparation method of cyclic chiral nitrile compound and application of cyclic chiral nitrile compound in preparation of ramelteon | 北京师范大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-117946050-A | Preparation method of ramelteon impurity dimer | 湖南慧泽生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-111116531-A | Preparation method of ramelteon intermediate | 山东省食品药品检验研究院 | 2020-05-08 | — | — | CN | disclosed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| CN-106632177-A | Preparation method of ramelteon intermediate | 万特制药(海南)有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-1100508-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| WO-1999063977-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-16 | — | — | WO | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | MTNR1B 3104/4885MTNR1A 3487/4885HTR2A 3093/4885 |
| US-20100234622-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | CYP2B6, CYP2A6, UGT1A6 | MTNR1B 779/4885MTNR1A 998/4885HTR2A 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.